<DOC>
	<DOCNO>NCT02473237</DOCNO>
	<brief_summary>Chronic Obstructive Pulmonary Disease ( COPD ) secondary biomass exposure constitute chronic respiratory condition frequently exclude large clinical trial . Biomass exposure COPD histopathologic , clinical , radiological functional difference tobacco smoke COPD . However , , evidence patient clinical response bronchodilator routinely use tobacco smoke COPD . Primary objective : To compare change walk meter baseline six minute walk test ( 6MWT ) 23:45 hour one dose indacaterol vs tiotropium patient moderate severe COPD secondary biomass exposure . Secondary objective : To compare change pulmonary function ( inspiratory capacity , Forced Expiratory Volume first second ( FEV1 ) milliliter , FEV1 `` '' ) baseline ( -10 minute ) 23:45 hour one dose indacaterol vs tiotropium patient moderate severe COPD secondary biomass exposure . This open label study , double blind , cross conduct specialized respiratory care center ( National Institute Respiratory Diseases ) , compare acute effect ultra long act bronchodilator use tobacco smoke exposure COPD . Unicentric study . Ethics Committee approbation : C 22-12</brief_summary>
	<brief_title>Efficacy Walked Distance Indacaterol v Tiotropium Women With COPD Secondary Biomass ( EMERALD )</brief_title>
	<detailed_description>Background : Until , COPD secondary biomass exposure treat similar way COPD due tobacco smoke . Unfortunately none clinical trial include patient biomass exposure multicenter study . COPD due biomass exposure common Mexico sub-developed country , represent high economy burden similar tobacco exposure . In Mexico , reference center COPD ( National Institute Respiratory Disease ) thirty percent woman attend COPD antecedent cook biomass . These patient predominant airway component , rather emphysema . These patient chronic bronchitis main clinical picture consequence , exacerbation . Additionally , present symptom dyspnea , COPD secondary tobacco exposure , functional inspiratory capacity reduce . There previous study describe acute effect long act bronchodilator like salmeterol functional inspiratory capacity . However , do patient COPD secondary tobacco smoke study do patient COPD secondary biomass exposition . Indacaterol novel long-acting bronchodilator provide 24 h bronchodilation once-daily dose fast onset action . Assuming condition patient COPD secondary biomass exposure ( woman , rural suburban origin , etc . ) necessary strategy enhance adherence . There information good adherence least frequency drug . Tiotropium provide 24 h bronchodilation once-daily dose slow onset action , select widely use treatment COPD drug therapeutic class ( long act antimuscarinic bronchodilator ) available market . Until international national report experience bronchodilator COPD secondary biomass . This first clinical trial world attempt evaluate acute effect ( fast onset action ) two long act bronchodilator , woman COPD secondary biomass exposure . Besides , result help highlight need rest world include patient different multicenter study . Primary objective : To compare change walk meter baseline six minute walk test ( 6MWT ) 23:45 hour one dose Indacaterol ( 150µg ) v Tiotropium ( 18µg ) patient moderate severe COPD secondary biomass exposure . Secondary efficacy Objectives : 1 . To compare change Inspiratory Capacity ( IC ) baseline ( -10 minute ) 30 , 60 , 240 minute 23:45 hour post dose Indacaterol ( 150 µg ) v Tiotropium ( 18µg ) patient biomass smoke COPD . 2 . To compare change FEV1 baseline ( -10 minute ) 30 , 60 , 240 min 23:45 hour post dose Indacaterol ( 150 µg ) v Tiotropium ( 18µg ) patient biomass smoke COPD . 3 . To compare 'trough ' FEV1 ( mean value 23 h 10 min 23 h 45 min post-dose ) one dose indacaterol vs tiotropium patient COPD secondary biomass exposure . 4 . To compare change dyspnea perception use Borg scale baseline ( -10 minute ) 30 , 60 , 240 min 23:45 hour post dose Indacaterol ( 150 µg ) v Tiotropium ( 18 µg ) patient COPD secondary biomass exposure . 5 . To compare frequency adverse event present study , indacaterol v tiotropium arm . Methodology : This open label study conduct specialized respiratory care center ( National Institute Respiratory Diseases , Mexico ) compare 24 hour response two long act bronchodilator ( Indacaterol v Tiotropium ) , one inhale dose . The primary endpoint change walk meter ( 6MWT ) baseline 30 , 60 , 120 240 minute post dose Indacaterol ( 150 µg ) v Tiotropium ( 18µg ) patient moderate severe COPD secondary biomass exposure . The key secondary endpoint 'trough ' FEV1 milliliter ( mean value 23 h 10 min 23 h 45 min ) post dose Indacaterol ( 150 µg ) v Tiotropium ( 18 µg ) patient moderate severe COPD secondary biomass exposure . The `` trough '' FEV1 value base mean two measurement take 23 h 10 min 23 h 45 min follow previous day 's morning dose . Other secondary endpoint : - FEV1 ( milliliter ) Inspiratory Capacity ( IC milliliter ) measure frpm baseline ( -10 min ) 30 , 60 , 90 , 120 240 minute post bronchodilator . - Dyspnea perception measure 10 point Borg scale , baseline 30 , 60 , 120 240 minute post bronchodilator . In patient spirometry perform serially 24 h postdose . The design imply crossover treatment order avoid variability subject guarantee outcome measure . There 40 intervention patient 40 control ( crossover design ) . The study comprise pre-screening visit , 7-day screening period , one day , 1-week treatment period . At baseline visit , eligible patient randomize equally one two treatment sequence ( A B ) receive either indacaterol 150 µg once-daily Tiotropium 18 µg once-daily , follow bronchodilator ( Tiotropium Indacaterol ) via single-dose dry powder inhaler ( SDDPI ) . Each treatment period separate washout period 7 day . Number center &amp; patient : 1 center 40 patient , sequentially expose two option treatment control . It decide make self control design crossover treatment order avoid variability subject guarantee outcome measure . Sample size justification : The sample size calculate consider power 80 % alpha value 0.05 two tail . Taking minimal clinical significance value 6 minute walk test 54 meter standard deviation 95 meter ( BODE study ) . Because design study investigator expect minimal patient withdrawn ( le 10 % ) . Population : It know COPD secondary biomass exposure patient commonly frequent exacerbation phenotype compare patient COPD secondary tobacco smoke , investigator also expect phenotype would major benefit therapy . That´s include COPD patient group B , C D , accord GOLD update 2011 . Pharmacovigilance requirement : All Adverse Events ( AE ) would report following procedure Serious Adverse Events ( SAEs ) Report . In order guarantee safety patient , AE occur patient begin treatment indacaterol . All recurrence , complication progression original AE must report follow original event , matter present . This report submit first 24 hour treat physician receive notification . Any AE consider related previous report AE , inform new event . All SAEs shall collect register Serious Adverse Event Report Form . Outcome measurement : Primary : Walked meter six minute walk test . Secondary : inspiratory capacity post bronchodilator measure change basal measure . 1 . Changes baseline pulmonary function inspiratory capacity . 2 . Changes baseline total score Borg scale dyspnea measure .</detailed_description>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>1 . Mexican patient COPD outpatient clinic 2 . Age : &gt; 50 3 . Female ( female eligibility criterion : Women fertile age non pregnant commit use effective contraception ) . 4 . FEV1 le 80 % predict risk exacerbation ( GOLD update 2011 ) B , C D 5 . Women COPD diagnostic biomass exposition ( defined Hours/years index &gt; 200 hr/y ) . 6 . Be Able assist different visit study . 7 . Be Able perform spirometry 8 . Patients without contraindication perform sixminute walk test . 9 . Informed consent sign . 10 . No history exacerbation last 6 week previous inclusion . 11 . With amenorrhea history year duration . 1 . Pregnant breastfeed woman 2 . Use Methotrexate , gold salt , troleandomycin , cyclosporine , immunosuppressant , 3 . History uncontrolled renal disease , liver disease , uncontrolled cardiovascular disease , metabolic disease , neurologic disease , hematologic disease , oncologic disease , autoimmune disease . 4 . Any alteration normal value follow Laboratory test : liver test , PIE , Biochemistry test . 5 . History asthma , bronchiectases , tuberculosis , recent respiratory tract infection , hospitalize COPD exacerbation ( 6 week prior visit 1 ) , significant pulmonary disease cardiovascular abnormality 6 . Patients suspicion cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>COPD</keyword>
	<keyword>biomass</keyword>
</DOC>